Cargando…
Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). Several MET exon 14 skipping alterations have been identified, but different MET exon splice variants tend to have different cl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015670/ https://www.ncbi.nlm.nih.gov/pubmed/35444936 http://dx.doi.org/10.3389/fonc.2022.863560 |
_version_ | 1784688363298619392 |
---|---|
author | Li, Jian Feng, Yun Tan, Yuan Duan, Qianqian Zhang, Qin |
author_facet | Li, Jian Feng, Yun Tan, Yuan Duan, Qianqian Zhang, Qin |
author_sort | Li, Jian |
collection | PubMed |
description | A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). Several MET exon 14 skipping alterations have been identified, but different MET exon splice variants tend to have different clinical outcomes which deserve concern. Herein, based on NGS panel analysis, we firstly described a 61-year-old woman with lung adenocarcinoma who harbored a novel MET exon 14 skipping (c.3004_3028+3del) concurrent MET amplification (copy number: 3.91) and benefited from Savolitinib treatment. Moreover, CytoTest MET/CCP7 FISH Probe (c-MET/CCP7 Ratio:1.41 and mean gene copy number:6) and qPCR which based on ABI 7500 also were performed to confirm these two MET alterations. After 2 months of Savolitinib treatment, the clinical evaluation was a partial response (PR). In summary, our finding not only expanded the spectrum of the MET exon14 variant (METex14). Targeted NGS analysis could improve detection of MET alterations in routine practice. |
format | Online Article Text |
id | pubmed-9015670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90156702022-04-19 Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib Li, Jian Feng, Yun Tan, Yuan Duan, Qianqian Zhang, Qin Front Oncol Oncology A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). Several MET exon 14 skipping alterations have been identified, but different MET exon splice variants tend to have different clinical outcomes which deserve concern. Herein, based on NGS panel analysis, we firstly described a 61-year-old woman with lung adenocarcinoma who harbored a novel MET exon 14 skipping (c.3004_3028+3del) concurrent MET amplification (copy number: 3.91) and benefited from Savolitinib treatment. Moreover, CytoTest MET/CCP7 FISH Probe (c-MET/CCP7 Ratio:1.41 and mean gene copy number:6) and qPCR which based on ABI 7500 also were performed to confirm these two MET alterations. After 2 months of Savolitinib treatment, the clinical evaluation was a partial response (PR). In summary, our finding not only expanded the spectrum of the MET exon14 variant (METex14). Targeted NGS analysis could improve detection of MET alterations in routine practice. Frontiers Media S.A. 2022-04-04 /pmc/articles/PMC9015670/ /pubmed/35444936 http://dx.doi.org/10.3389/fonc.2022.863560 Text en Copyright © 2022 Li, Feng, Tan, Duan and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Jian Feng, Yun Tan, Yuan Duan, Qianqian Zhang, Qin Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib |
title | Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib |
title_full | Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib |
title_fullStr | Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib |
title_full_unstemmed | Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib |
title_short | Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib |
title_sort | case report: a lung adenocarcinoma with brain metastasis harbored novel met 14 skipping alteration sensitive to savolitinib |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015670/ https://www.ncbi.nlm.nih.gov/pubmed/35444936 http://dx.doi.org/10.3389/fonc.2022.863560 |
work_keys_str_mv | AT lijian casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib AT fengyun casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib AT tanyuan casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib AT duanqianqian casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib AT zhangqin casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib |